ArticleFrontiers in toxicology2025
Medium cut-off membrane expanded hemodialysis for Lithium removal: a case report.
Article in Frontiers in toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lithium remains a first-line treatment for bipolar disorder, though its narrow therapeutic window poses a significant risk of toxicity. Severe intoxication can lead to neurologic, renal, gastrointestinal, and endocrine complications. Extracorporeal therapies are the mainstay in managing life-threatening cases, particularly when serum concentration exceed 4.0 mmol/L or when renal function is impaired. Intermittent hemodialysis (HD) is the recommended extracorporeal treatment due to lithium's low molecular weight and minimal protein binding. Expanded hemodialysis (HDx) with medium cut-off (MCO) membranes, designed to enhance solute clearance, may represent a promising alternative. Case Report: We present a case of acute lithium intoxication in a 48-year-old male with a history of recurrent suicidal behavior and chronic lithium therapy. The patient arrived at the emergency department in a deep coma (GCS 3), with a serum lithium concentration of 4.5 mmol/L and preserved renal function. He underwent two intermittent HDx sessions using a Theranova® TH-400 MCO membrane. Serum lithium concentration declined to 1.6 mmol/L after the first session and progressively to 0.1 mmol/L within 72 h. No treatment-related complications were observed. Conclusion: This case described the potential utility of HDx with the MCO membrane (Theranova® 400) in managing severe lithium poisoning, achieving effective and sustained drug clearance. While HDx-MCO may offer a viable alternative to conventional HD, especially in settings where enhanced solute removal is desirable, further studies are needed to determine its efficacy and clinical role in lithium toxicity management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.